From bench to bedside: Unveiling the background and benefits of nanovaccines tested in clinics

Vera S. Egorova , Ekaterina P. Kolesova , Maya V. Voronina , Evgenya R. Denisova , Anastasiia O. Syrocheva , Tatiana Pallaeva , Mazdak G. Hakemi , Andrey A. Zamyatnin Jr. , Konstantin I. Ivanov , Dmitry Kostyushev , Sergey Brezgin , Anastasiia Kostyusheva , Alessandro Parodi

Asian Journal of Pharmaceutical Sciences ›› 2026, Vol. 21 ›› Issue (1) : 101116

PDF (2769KB)
Asian Journal of Pharmaceutical Sciences ›› 2026, Vol. 21 ›› Issue (1) :101116 DOI: 10.1016/j.ajps.2026.101116
Review Article
research-article
From bench to bedside: Unveiling the background and benefits of nanovaccines tested in clinics
Author information +
History +
PDF (2769KB)

Abstract

Despite the growing body of literature on nanovaccines, focused analyses of platforms tested in and undergoing clinical investigation remain limited. This review addresses this gap by critically examining recent advancements and highlighting nanovaccine technologies that have undergone human clinical trials. Using an extensive search on clinicaltrials.org, we explored the diverse applications of nanovaccines, including leading SARS-CoV-2 candidates and platforms targeting other infectious diseases and cancers. We also highlighted foundational research that has enabled clinical investigation of nanovaccines over the past decade, highlighting their potential to address a range of medical conditions. While many technologies have been developed to combat SARS-CoV-2, several key innovations targeted a broader spectrum of diseases. This review details these technologies, focusing on their materials and mechanisms of action in inducing immune protection, while also exploring how nanomedicine facilitates nanovaccine development and introduces novel adjuvant concepts. Finally, we provided a retrospective analysis of the development journey of these platforms, offering insights into the intellectual and technological efforts behind their clinical translation. By bridging the gap between research and application, this review aims to give readers a comprehensive understanding of how nanovaccines progress from the laboratory to clinical practice.

Keywords

Nanovaccine / Lipid nanoparticle / Virus-like nanoparticles / Outer membrane vesicles / Ferritin nanovaccines

Cite this article

Download citation ▾
Vera S. Egorova, Ekaterina P. Kolesova, Maya V. Voronina, Evgenya R. Denisova, Anastasiia O. Syrocheva, Tatiana Pallaeva, Mazdak G. Hakemi, Andrey A. Zamyatnin Jr., Konstantin I. Ivanov, Dmitry Kostyushev, Sergey Brezgin, Anastasiia Kostyusheva, Alessandro Parodi. From bench to bedside: Unveiling the background and benefits of nanovaccines tested in clinics. Asian Journal of Pharmaceutical Sciences, 2026, 21 (1) : 101116 DOI:10.1016/j.ajps.2026.101116

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Parodi A, Kolesova EP, Voronina MV, Frolova AS, Kostyushev D, Trushina DB, et al. Anticancer nanotherapeutics in clinical trials: the work behind clinical translation of nanomedicine. Int J Mol Sci 2022; 23(22): 13368.

[2]

Evangelopoulos M, Parodi A, Martinez JO, Tasciotti E. Trends towards biomimicry in theranostics. Nanomaterials (Basel) 2018; 8(9): 637.

[3]

Dirisala A, Li J, Gonzalez Carter D, Zheng W. The power of delivery systems in biologics. Front Bioeng Biotechnol 2023; 11: 1274210.

[4]

Rodrigues MQ, Alves PM, Roldão A. Functionalizing ferritin nanoparticles for vaccine development. Pharmaceutics 2021; 13(10): 1621.

[5]

Karch CP, Burkhard P. Vaccine technologies: from whole organisms to rationally designed protein assemblies. Biochem Pharmacol 2016; 120: 1-14.

[6]

Chen J, Ye Z, Huang C, Qiu M, Song D, Li Y, et al. Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8+ T cell response. Proc Natl Acad Sci U S A 2022; 119(34): e2207841119.

[7]

El-Sayed N, Korotchenko E, Scheiblhofer S, Weiss R, Schneider M. Functionalized multifunctional nanovaccine for targeting dendritic cells and modulation of immune response. Int J Pharm 2021; 593: 120123.

[8]

Liu H, Chen H, Yang Z, Wen Z, Gao Z, Liu Z, et al. Precision nanovaccines for potent vaccination. JACS Au 2024; 4(6): 2792-810.

[9]

Li S, Feng X, Wang J, Xu W, Islam MA, Sun T, et al. Multiantigenic nanoformulations activate anticancer immunity depending on size. Adv Funct Mater 2019; 29(51): 1903391.

[10]

Rehm BH. Bioengineering towards self-assembly of particulate vaccines. Curr Opin Biotechnol 2017; 48: 42-53.

[11]

Ahmad MZ, Ahmad J, Haque A, Alasmary MY, Abdel-Wahab BA, Akhter S, et al. Emerging advances in synthetic cancer nano-vaccines: opportunities and challenges. Expert Rev Vaccines 2020; 19(11): 1053-71.

[12]

Yadav HK, Dibi M, Mohammad A, Srouji AE. Nanovaccines formulation and applications-a review. J Drug Deliv Sci Technol 2018; 44: 380-7.

[13]

Sarangi MK, Padhi S, Rath G, Nanda SS, Yi DK. Success of nano-vaccines against COVID-19: a transformation in nanomedicine. Expert Rev Vaccines 2022; 21(12): 1739-61.

[14]

Zaccariotto GC, Bistaffa MJ, Zapata AMM, Rodero C, Coelho F, Quitiba JVB, et al. Cancer nanovaccines: mechanisms, design principles, and clinical translation. ACS Nano 2025; 19(13): 16204-23.

[15]

Statista. Number of coronavirus (COVID-19) cases, recoveries, and deaths worldwide as of May 2, 2023. Available at: https://www.statista.com/statistics/1087466/covid19-cases-recoveries-deaths-worldwide/. (Accessed January 30, 2026)

[16]

Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010; 375(9725): 1545-55.

[17]

Modjarrad K, Giersing B, Kaslow DC, Smith PG, Moorthy VSGroup WRVCE. WHO consultation on respiratory syncytial virus vaccine development report from a World Health Organization meeting held on 23-24 March 2015. Vaccine 2016; 34(2): 190-7.

[18]

Muñoz FM, Swamy GK, Hickman SP, Agrawal S, Piedra PA, Glenn GM, et al. Safety and immunogenicity of a respiratory syncytial virus fusion (F) protein nanoparticle vaccine in healthy third-trimester pregnant women and their infants. J Infect Dis 2019; 220(11): 1802-15.

[19]

Powell AE, Xu D, Roth GA, Zhang K, Chiu W, Appel EA, et al. Multimerization of Ebola GP mucin on protein nanoparticle vaccines has minimal effect on elicitation of neutralizing antibodies. Front Immunol 2022; 13: 942897.

[20]

Wu F, Zhang S, Zhang Y, Mo R, Yan F, Wang H, et al. A chimeric Sudan virus-like particle vaccine candidate produced by a recombinant baculovirus system induces specific immune responses in mice and horses. Viruses 2020; 12(1): 64.

[21]

Clinic M. Dengue fever. Available at: https://www.mayoclinic.org/diseases-conditions/dengue-fever/symptoms-causes/syc-20353078#:~:text=Dengue%20fever%20is%20most%20common,working%20on%20dengue%20fever%20vaccines. (Accessed January 30, 2026)

[22]

Quach QH, Ang SK, Chu JHJ, Kah JCY. Size-dependent neutralizing activity of gold nanoparticle-based subunit vaccine against dengue virus. Acta Biomater 2018; 78: 224-35.

[23]

Guo M, Yao Z, Jiang C, Songyang Z, Gan L, Xiong Y. Three-dimensional and single-cell sequencing of liver cancer reveals comprehensive host-virus interactions in HBV infection. Front Immunol 2023; 14: 1161522.

[24]

Ruzzi F, Semprini MS, Scalambra L, Palladini A, Angelicola S, Cappello C, et al. Virus-like particle (VLP) vaccines for cancer immunotherapy. Int J Mol Sci 2023; 24(16): 12963.

[25]

Chen F, Li S, Guo R, Song F, Zhang Y, Wang X, et al. Meta-analysis of fecal viromes demonstrates high diagnostic potential of the gut viral signatures for colorectal cancer and adenoma risk assessment. J Adv Res 2023; 49: 103-14.

[26]

Hollingsworth RE, Jansen K. Turning the corner on therapeutic cancer vaccines. NPJ Vaccines 2019; 4: 7.

[27]

Van Ranst M, Zöllner Y, Schelling J, Palache B. The burden of seasonal influenza: improving vaccination coverage to mitigate morbidity and its impact on healthcare systems. Expert Rev Vaccines 2023; 22(1): 518-19.

[28]

Putri WC, Muscatello DJ, Stockwell MS, Newall AT. Economic burden of seasonal influenza in the United States. Vaccine 2018; 36(27): 3960-6.

[29]

Munoz N. Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol 2000; 19(1-2): 1-5.

[30]

Jach R, Basta A, Kotarski J, Markowska J, Paszkowski T, Dębski R, et al. Ten years of anti-HPV vaccinations: what do we know? Menopause Rev 2016; 15(3): 170-5.

[31]

Institute NC. HPV and cancer. Available at: https://visualsonline.cancer.gov/details.cfm?imageid=11921. (Accessed January 30, 2026)

[32]

Zanini F, Puller V, Brodin J, Albert J, Neher RA. In vivo mutation rates and the landscape of fitness costs of HIV-1. Virus Evol 2017; 3(1): vex003.

[33]

Castro-Gonzalez S, Colomer-Lluch M, Serra-Moreno R. Barriers for HIV cure: the latent reservoir. AIDS Res Hum Retroviruses 2018; 34(9): 739-59.

[34]

Organization WH. Malaria by numbers: global and regional burden. Available at: https://www.who.int/campaigns/world-malaria-day/2023/background. (Accessed January 30, 2026)

[35]

Cohen JI, Fauci AS, Varmus H, Nabel GJ. Epstein-Barr virus: an important vaccine target for cancer prevention. Sci Transl Med 2011; 3(107): 107fs7.

[36]

Kanekiyo M, Bu W, Joyce MG, Meng G, Whittle JR, Baxa U, et al. Rational design of an Epstein-Barr virus vaccine targeting the receptor-binding site. Cell 2015; 162(5): 1090-100.

[37]

Gregoriadis G. Liposomes and mRNA: two technologies together create a COVID-19 vaccine. Med Drug Discov 2021; 12: 100104.

[38]

Gregoriadis G, Allison AC. Entrapment of proteins in liposomes prevents allergic reactions in pre-immunised mice. FEBS Lett 1974; 45(1): 71-4.

[39]

Ambrosch F, Wiedermann G, Jonas S, Althaus B, Finkel B, Glück R, et al. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 1997; 15(11): 1209-13.

[40]

Bovier PA. Epaxal®: a virosomal vaccine to prevent hepatitis A infection. Expert Rev Vaccines 2008; 7(8): 1141-50.

[41]

Abdoli A, Soleimanjahi H, Kheiri MT, Jamali A, Sohani H, Abdoli M, et al. Reconstruction of H3N2 influenza virus based virosome in-vitro . Iran J Microbiol 2013; 5(2): 166.

[42]

Agency EM. Assessment report Comirnaty common name: COVID-19 mRNA vaccine (nucleoside-modified); EMEA/H/C/005735/0000; 2020. Available at: https://www.huber.embl.de/msmb/extras/comirnaty-epar-public-assessment-report_en.pdf. (Accessed January 30, 2026)

[43]

Agency EM. Assessment report COVID-19 Vaccine Moderna common name: COVID-19 mRNA vaccine (nucleoside-modified) EMEA/H/C/005791/0000; 2021. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/spikevax. (Accessed January 30, 2026)

[44]

Lewis LM, Badkar AV, Cirelli D, Combs R, Lerch TF. The race to develop the Pfizer-BioNTech COVID-19 vaccine: from the pharmaceutical scientists’ perspective. J Pharm Sci 2023; 112(3): 640-7.

[45]

Pfizer. Pfizer and BioNTech to Co-develop potential COVID-19 vaccine. Available at: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-co-develop-potential-covid-19-vaccine. (Accessed January 30, 2026)

[46]

Fathizadeh H, Afshar S, Masoudi MR, Gholizadeh P, Asgharzadeh M, Ganbarov K, et al. SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effectiveness: a review. Int J Biol Macromol 2021; 188: 740-50.

[47]

Mashaghi S, Jadidi T, Koenderink G, Mashaghi A. Lipid nanotechnology. Int J Mol Sci 2013; 14(2): 4242-82.

[48]

Let’s talk about lipid nanoparticles. Nat Rev Mater 2021; 6: 99. doi: 10.1038/s41578-021-00281-4.

[49]

Kulkarni JA, Witzigmann D, Chen S, Cullis PR, van der Meel R. Lipid nanoparticle technology for clinical translation of siRNA therapeutics. Acc Chem Res 2019; 52(9): 2435-2444.

[50]

Yan J, Kang DD, Dong Y. Harnessing lipid nanoparticles for efficient CRISPR delivery. Biomater Sci 2021; 9(18): 6001-11.

[51]

Li Y, Ye Z, Yang H, Xu Q. Tailoring combinatorial lipid nanoparticles for intracellular delivery of nucleic acids, proteins, and drugs. Acta Pharm Sin B 2022; 12(6): 2624-2639.

[52]

Syama K, Jakubek ZJ, Chen S, Zaifman J, Tam YYC, Zou S. Development of lipid nanoparticles and liposomes reference materials (II): cytotoxic profiles. Sci Rep 2022; 12(1): 18071.

[53]

Li S, Wang W, Yu X. A perspective of engineered lipids and liposomes: chemical design and functional application based on therapeutic safety. Chem Mater 2023; 35(12): 4587-97.

[54]

Chen YJ, Paul A, Collins MG, Lee HY. The changing landscape of gene editing tool delivery in neurological disorders. Curr Opin Biomed Eng 2023; 28: 100509.

[55]

Alesci A, Gitto M, Kotańska M, Cascio PL, Miller A, Nicosia N, et al. Immunogenicity, effectiveness, safety and psychological impact of COVID-19 mRNA vaccines. Hum Immunol 2022; 83(10): 755-67.

[56]

Wang Q, Wang Z, Sun X, Jiang Q, Sun B, He Z, et al. Lymph node-targeting nanovaccines for cancer immunotherapy. J Control Release 2022; 351: 102-22.

[57]

Yu X, Dai Y, Zhao Y, Qi S, Liu L, Lu L, et al. Melittin-lipid nanoparticles target to lymph nodes and elicit a systemic anti-tumor immune response. Nat Commun 2020; 11(1): 1110.

[58]

Kuai R, Ochyl LJ, Bahjat KS, Schwendeman A, Moon JJ. Designer vaccine nanodiscs for personalized cancer immunotherapy. Nat Mater 2017; 16(4): 489-96.

[59]

Kim Y, Kang S, Shin H, Kim T, Yu B, Kim J, et al. Sequential and timely combination of a cancer nanovaccine with immune checkpoint blockade effectively inhibits tumor growth and relapse. Angew Chem Int Ed Engl 2020; 59(34): 14728-38.

[60]

Albertsen CH, Kulkarni JA, Witzigmann D, Lind M, Petersson K, Simonsen JB. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv Drug Deliv Rev 2022; 188: 114416.

[61]

Wang MM, Wappelhorst CN, Jensen EL, Chi YCT, Rouse JC, Zou Q. Elucidation of lipid nanoparticle surface structure in mRNA vaccines. Sci Rep 2023; 13(1): 16744.

[62]

Kurimoto S, Yoshinaga N, Igarashi K, Matsumoto Y, Cabral H, Uchida S. PEG-OligoRNA hybridization of mRNA for developing sterically stable lipid nanoparticles toward in vivo administration . Molecules 2019; 24(7): 1303.

[63]

de Vrieze J. Pfizer’s vaccine raises allergy concerns. Science 2021; 371(6524): 10-11.

[64]

Bigini P, Gobbi M, Bonati M, Clavenna A, Zucchetti M, Garattini S, et al. The role and impact of polyethylene glycol on anaphylactic reactions to COVID-19 nano-vaccines. Nat Nanotechnol 2021; 16(11): 1169-71.

[65]

Shimabukuro TT, Cole M, Su JR. Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US-December 14, 2020-January 18, 2021. JAMA 2021; 325(11): 1101-2.

[66]

Paramasivam P, Franke C, Stöter M, Höijer A, Bartesaghi S, Sabirsh A, et al. Endosomal escape of delivered mRNA from endosomal recycling tubules visualized at the nanoscale. J Cell Biol 2021; 221(2): e202110137.

[67]

Khaled SZ, Cevenini A, Yazdi IK, Parodi A, Evangelopoulos M, Corbo C, et al. One-pot synthesis of pH-responsive hybrid nanogel particles for the intracellular delivery of small interfering RNA. Biomaterials 2016; 87: 57-68.

[68]

Sahay G, Querbes W, Alabi C, Eltoukhy A, Sarkar S, Zurenko C, et al. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat Biotechnol 2013; 31(7): 653-8.

[69]

Parodi A, Evangelopoulos M, Arrighetti N, Cevenini A, Livingston M, Khaled SZ, et al. Endosomal escape of polymer-coated silica nanoparticles in endothelial cells. Small 2020; 16(15): 1907693.

[70]

Akinc A, Querbes W, De S, Qin J, Frank-Kamenetsky M, Jayaprakash KN, et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther 2010; 18(7): 1357-64.

[71]

Hassett KJ, Benenato KE, Jacquinet E, Lee A, Woods A, Yuzhakov O, et al. Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. Mol Ther Nucleic Acids 2019; 15: 1-11.

[72]

Patel P, Ibrahim NM, Cheng K. The importance of apparent pKa in the development of nanoparticles encapsulating siRNA and mRNA. Trends Pharmacol Sci 2021; 42(6): 448-60.

[73]

Pizzuto M, Gangloff M, Scherman D, Gay NJ, Escriou V, Ruysschaert JM, et al. Toll-like receptor 2 promiscuity is responsible for the immunostimulatory activity of nucleic acid nanocarriers. J Control Release 2017; 247: 182-93.

[74]

Zaqout A, Daghfal J, Alaqad I, Hussein SA, Aldushain A, Almaslamani MA, et al. The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout. Int J Infect Dis 2021; 108: 116-18.

[75]

Thompson MG, Burgess JL, Naleway AL, Tyner H, Yoon SK, Meece J, et al. Prevention and attenuation of Covid-19 with the BNT162b2 and mRNA-1273 vaccines. N Engl J Med 2021; 385(4): 320-9.

[76]

Teo SP. Review of COVID-19 mRNA vaccines: BNT162b2 and mRNA-1273. J Pharm Pract 2022; 35(6): 947-51.

[77]

Cohen J. What went wrong with CureVac’s mRNA vaccine? Science 2021; 372(6549): 1381.

[78]

Kowalzik F, Schreiner D, Jensen C, Teschner D, Gehring S, Zepp F. mRNA-based vaccines. Vaccines (Basel) 2021; 9(4): 390.

[79]

Pascolo S. Synthetic messenger RNA-based vaccines: from scorn to hype. Viruses 2021; 13(2): 270.

[80]

Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA vaccines. Circulation 2021; 144(6): 471-84.

[81]

Pepe S, Gregory AT, Denniss AR. Myocarditis, pericarditis and cardiomyopathy after COVID-19 vaccination. Heart Lung Circ 2021; 30(11): 1425-9.

[82]

Lee IT, Nachbagauer R, Ensz D, Schwartz H, Carmona L, Schaefers K, et al. Safety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis. Nat Commun 2023; 14(1): 3631.

[83]

Deo S, Desai K, Patare A, Wadapurkar R, Rade S, Mahudkar S, et al. Evaluation of self-amplifying mRNA platform for protein expression and genetic stability: implication for mRNA therapies. Biochem Biophys Res Commun 2023; 680: 108-18.

[84]

Saraf A, Gurjar R, Kaviraj S, Kulkarni A, Kumar D, Kulkarni R, et al. An omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial. Nat Med 2024; 30(5): 1363-72.

[85]

Gennova. GEMCOVAC® mRNA vaccines for COVID-19. Available at: https://gennova.bio/gemcovac-19-2/. (Accessed January 30, 2026)

[86]

Laturski AE, Dulay MT, Perry JL, DeSimone JM. Transfection via RNA-based nanoparticles: comparing encapsulation vs adsorption approaches of RNA incorporation. Bioconjug Chem 2025; 36(2): 367-76.

[87]

Qi S, Wang H, Liu G, Qin Q, Gao P, Ying B. Efficient circularization of protein-encoding RNAs via a novel cis-splicing system. Nucleic Acids Res 2024; 52(18): 10400-15.

[88]

Arevalo CP, Bolton MJ, Le Sage V, Ye N, Furey C, Muramatsu H, et al. A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes. Science 2022; 378(6622): 899-904.

[89]

Mohsen MO, Gomes AC, Vogel M, Bachmann MF. Interaction of viral capsid-derived virus-like particles (VLPs) with the innate immune system. Vaccines (Basel) 2018; 6(3): 37.

[90]

Qian C, Liu X, Xu Q, Wang Z, Chen J, Li T, et al. Recent progress on the versatility of virus-like particles. Vaccines (Basel) 2020; 8(1): 139.

[91]

Nooraei S, Bahrulolum H, Hoseini ZS, Katalani C, Hajizade A, Easton AJ, et al. Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J Nanobiotechnology 2021; 19(1): 59.

[92]

Ward BJ, Makarkov A, Séguin A, Pillet S, Trépanier S, Dhaliwall J, et al. Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18-64 years) and older adults (≥ 65 years): two multicentre, randomised phase 3 trials. Lancet 2020; 396(10261): 1491-503.

[93]

Parodi A, Molinaro R, Sushnitha M, Evangelopoulos M, Martinez JO, Arrighetti N, et al. Bio-inspired engineering of cell-and virus-like nanoparticles for drug delivery. Biomaterials 2017; 147: 155-68.

[94]

Sharifzadeh M, Mottaghi-Dastjerdi N, Raad MSR. A review of virus-like particle-based SARS-CoV-2 vaccines in clinical trial phases. Iran J Pharm Res 2022; 21(1): e127042.

[95]

Shiri F, Petersen KE, Romanov V, Zou Q, Gale BK. Characterization and differential retention of Q beta bacteriophage virus-like particles using cyclical electrical field-flow fractionation and asymmetrical flow field-flow fractionation. Anal Bioanal Chem 2020; 412(7): 1563-72.

[96]

Ramirez A, Morris S, Maucourant S, D’Ascanio I, Crescente V, Lu IN, et al. A virus-like particle vaccine candidate for influenza A virus based on multiple conserved antigens presented on hepatitis B tandem core particles. Vaccine 2018; 36(6): 873-80.

[97]

Lacson E, Teng M, Ong J, Vienneau L, Ofsthun N, Lazarus JM. Antibody response to Engerix-B® and Recombivax-HB® hepatitis B vaccination in end-stage renal disease. Hemodial Int 2005; 9(4): 367-75.

[98]

Coates T, Wilson R, Patrick G, André F, Watson V. Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clin Ther 2001; 23(3): 392-403.

[99]

Coates EE, Edupuganti S, Chen GL, Happe M, Strom L, Widge A, et al. Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial. Lancet Infect Dis 2022; 22(8): 1210-20.

[100]

Chen GL, Coates EE, Plummer SH, Carter CA, Berkowitz N, Conan-Cibotti M, et al. Effect of a chikungunya virus-like particle vaccine on safety and tolerability outcomes: a randomized clinical trial. JAMA 2020; 323(14): 1369-77.

[101]

Bennett SR, McCarty JM, Ramanathan R, Mendy J, Richardson JS, Smith J, et al. Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial. Lancet Infect Dis 2022; 22(9): 1343-55.

[102]

Olsson SE, Restrepo JA, Reina JC, Pitisuttithum P, Ulied A, Varman M, et al. Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: interim analysis after 8 years of follow-up. Papillomavirus Res 2020; 10: 100203.

[103]

Murata S, Takeuchi Y, Yamanaka K, Hayakawa J, Yoshida M, Yokokawa R, et al. Safety and immunogenicity of the quadrivalent HPV vaccine in Japanese boys: a phase 3, open-label study. Jpn J Infect Dis 2019; 72(4): 299-305.

[104]

Joura EA, Ulied A, Vandermeulen C, Figueroa MR, Seppä I, Aguado JJH, et al. Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: an open-label phase 3 study. Vaccine 2021; 39(20): 2800-9.

[105]

Kapoor AN, Tharyan P, Kant L, Balraj V, Shemilt I. Combined DTP-HBV vaccine versus separately administered DTP and HBV vaccines for primary prevention of diphtheria, tetanus, pertussis, and hepatitis B . Cochrane Database Syst Rev 2017; 2017(4): CD010845.

[106]

Keating GM, Noble S. Recombinant hepatitis B vaccine (Engerix-B®) a review of its immunogenicity and protective efficacy against hepatitis B. Drugs 2003; 63(10): 1021-51.

[107]

Harjeet K, Mani A. Seroprotection following Enivac-HB, a recombinant hepatitis B vaccine. Indian J Gastroenterol 2000; 19(1): 41.

[108]

Madhuri D, Viveka Vardhani V. GST level in the abdominal muscles of mice treated with Immunex DS and Gene Vac B vaccine. Biolife 2015; 3(1): 26-30.

[109]

Zhao Q, Towne V, Brown M, Wang Y, Abraham D, Oswald CB, et al. In-depth process understanding of RECOMBIVAX HB® maturation and potential epitope improvements with redox treatment: multifaceted biochemical and immunochemical characterization. Vaccine 2011; 29(45): 7936-41.

[110]

Sucher AJ, Sucher BJ, Chahine EB. PreHevbrio: a new 3-antigen hepatitis B vaccine for adults. Ann Pharmacother 2023; 57(3): 325-32.

[111]

Proffitt A. First HEV vaccine approved. Nat Biotechnol 2012; 30(4): 300-1.

[112]

Szarewski A. HPV vaccine: cervarix. Expert Opin Biol Ther 2010; 10(3): 477-87.

[113]

Yoshikawa H, Ebihara K, Tanaka Y, Noda K. Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18-26 years. Cancer Sci 2013; 104(4): 465-72.

[114]

Braaten KP, Laufer MR. Human papillomavirus (HPV), HPV-related disease, and the HPV vaccine. Rev Obstet Gynecol 2008; 1(1): 2.

[115]

Kunda NK, Peabody J, Zhai L, Price DN, Chackerian B, Tumban E, et al. Evaluation of the thermal stability and the protective efficacy of spray-dried HPV vaccine, Gardasil® 9. Hum Vaccin Immunother 2019; 15(7-8): 1995-2002.

[116]

You T, Zhao X, Hu S, Gao M, Liu Y, Zhang Y, et al. Optimal allocation strategies for HPV vaccination introduction and expansion in China accommodated to different supply and dose schedule scenarios: a modelling study. EClinicalMedicine 2023; 56: 101815.

[117]

Herzog C, Hartmann K, Künzi V, Kürsteiner O, Mischler R, Lazar H, et al. Eleven years of Inflexal® V-A virosomal adjuvanted influenza vaccine. Vaccine 2009; 27(33): 4381-4387.

[118]

Guebre-Xabier M, Patel N, Tian JH, Zhou B, Maciejewski S, Lam K, et al. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. Vaccine 2020; 38(50): 7892-6.

[119]

Ward BJ, Gobeil P, Séguin A, Atkins J, Boulay I, Charbonneau PY, et al. Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19. Nat Med 2021; 27(6): 1071-8.

[120]

Medicago. Plant-derived vaccines. Available at: https://www.nature.com/articles/d43747-020-00537-y. (Accessed January 30, 2026)

[121]

Canada H. Medicago Covifenz COVID-19 vaccine. Available at: https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/vaccines/medicago.html. (Accessed January 30, 2026)

[122]

D’Sa S, Braz Gomes K, Allotey-Babington GL, Boyoglu C, Kang SM, D’Souza MJ. Transdermal immunization with microparticulate RSV-F virus-like particles elicits robust immunity. Vaccines (Basel) 2022; 10(4): 584.

[123]

Smith G, Raghunandan R, Wu Y, Liu Y, Massare M, Nathan M, et al. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. PLoS One 2012; 7(11): e50852.

[124]

McLellan JS, Chen M, Kim A, Yang Y, Graham BS, Kwong PD. Structural basis of respiratory syncytial virus neutralization by motavizumab. Nat Struct Mol Biol 2010; 17(2): 248-50.

[125]

Patel N, Massare MJ, Tian JH, Guebre-Xabier M, Lu H, Zhou H, et al. Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: structure, antigenic profile, immunogenicity, and protection. Vaccine 2019; 37(43): 6112-24.

[126]

Glenn GM, Smith G, Fries L, Raghunandan R, Lu H, Zhou B, et al. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine 2013; 31(3): 524-32.

[127]

Fries L, Shinde V, Stoddard JJ, Thomas DN, Kpamegan E, Lu H, et al. Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults. Immun Ageing 2017; 14: 8.

[128]

August A, Glenn GM, Kpamegan E, Hickman SP, Jani D, Lu H, et al. A phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age. Vaccine 2017; 35(28): 3749-59.

[129]

Glenn GM, Fries LF, Thomas DN, Smith G, Kpamegan E, Lu H, et al. A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant fusion (F) nanoparticle vaccine in healthy women of childbearing age. J Infect Dis 2016; 213(3): 411-22.

[130]

Madhi SA, Polack FP, Piedra PA, Munoz FM, Trenholme AA, Simões EA, et al. Respiratory syncytial virus vaccination during pregnancy and effects in infants. N Engl J Med 2020; 383(5): 426-39.

[131]

Dieussaert I, Hyung Kim J, Luik S, Seidl C, Pu W, Stegmann JU, et al. RSV prefusion F protein-based maternal vaccine-Preterm birth and other outcomes. N Engl J Med 2024; 390(11): 1009-21.

[132]

Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG, et al. Efficacy and safety of respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons. Clin Infect Dis 2024; 78(6): 1732-44.

[133]

Walsh EE, Falsey AR, Zareba AM, Jiang Q, Gurtman A, Radley D, et al. Respiratory syncytial virus prefusion F vaccination: antibody persistence and revaccination. J Infect Dis 2024; 230(3): e905-16.

[134]

Karron RA, Luongo C, Woods S, Oliva J, Collins PL, Buchholz UJ, et al. Evaluation of the live-attenuated intranasal respiratory syncytial virus (RSV) vaccine RSV/6120/ NS2/1030s in RSV-seronegative young children. J Infect Dis 2024; 229(2): 346-54.

[135]

Wilson E, Goswami J, Baqui AH, Doreski PA, Perez-Marc G, Zaman K, et al. Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults. N Engl J Med 2023; 389(23): 2233-44.

[136]

Shaw CA, Mithani R, Kapoor A, Dhar R, Wilson L, El Asmar L, et al. Safety, tolerability, and immunogenicity of an mRNA-based respiratory syncytial virus vaccine in healthy young adults in a phase 1 clinical trial. J Infect Dis 2024; 230(3): e637-46.

[137]

Tariq H, Batool S, Asif S, Ali M, Abbasi BH. Virus-like particles: revolutionary platforms for developing vaccines against emerging infectious diseases. Front Microbiol 2022; 12: 790121.

[138]

Ding X, Liu D, Booth G, Gao W, Lu Y. Virus-like particle engineering: from rational design to versatile applications. Biotechnol J 2018; 13(2): 1700324.

[139]

Collins SM, Nice JB, Chang EH, Brown AC. Size exclusion chromatography to analyze bacterial outer membrane vesicle heterogeneity. J Vis Exp 2021(171): e62429.

[140]

Micoli F, MacLennan CA. Outer membrane vesicle vaccines. Semin Immunol 2020; 50: 101433.

[141]

Chatterjee S, Das J. Electron microscopic observations on the excretion of cell-wall material by Vibrio cholerae . J Gen Microbiol 1967; 49(1): 1-11.

[142]

Lieberman LA. Outer membrane vesicles: a bacterial-derived vaccination system. Front Microbiol 2022; 13: 1029146.

[143]

Balhuizen MD, Veldhuizen EJA, Haagsman HP. Outer membrane vesicle induction and isolation for vaccine development. Front Microbiol 2021; 12: 629090.

[144]

Toyofuku M, Nomura N, Eberl L. Types and origins of bacterial membrane vesicles. Nat Rev Microbiol 2019; 17(1): 13-24.

[145]

Toyofuku M, Schild S, Kaparakis-Liaskos M, Eberl L. Composition and functions of bacterial membrane vesicles. Nat Rev Microbiol 2023; 21(7): 415-30.

[146]

Dürwald A, Zühlke MK, Schlüter R, Gebbe R, Bartosik D, Unfried F, et al. Reaching out in anticipation: bacterial membrane extensions represent a permanent investment in polysaccharide sensing and utilization. Environ Microbiol 2021; 23(6): 3149-63.

[147]

Wang M, Nie Y, Wu XL. Extracellular heme recycling and sharing across species by novel mycomembrane vesicles of a gram-positive bacterium. ISME J 2021; 15(2): 605-17.

[148]

Augustyniak D, Olszak T, Drulis-Kawa Z. Outer membrane vesicles (OMVs) of Pseudomonas aeruginosa provide passive resistance but not sensitization to LPS-specific phages. Viruses 2022; 14(1): 121.

[149]

Andreoni F, Toyofuku M, Menzi C, Kalawong R, Mairpady Shambat S, François P, et al. Antibiotics stimulate formation of vesicles in Staphylococcus aureus in both phage-dependent and-independent fashions and via different routes. Antimicrob Agents Chemother 2019; 63(10) e01439-e01418.

[150]

Codemo M, Muschiol S, Iovino F, Nannapaneni P, Plant L, Wai SN, et al. Immunomodulatory effects of pneumococcal extracellular vesicles on cellular and humoral host defenses. mBio 2018; 9(2) e00559-e00518.

[151]

Yue H, Jiang J, Taylor AJ, Leite ADL, Dodds ED, Du L. Outer membrane vesicle-mediated codelivery of the antifungal HSAF metabolites and lytic polysaccharide monooxygenase in the predatory Lysobacter enzymogenes. ACS Chem Biol 2021; 16(6): 1079-89.

[152]

Intravacc. OMV-Vacc technology. Available at: https://www.intravacc.nl/platforms/omv-vacc-technology. (Accessed January 30, 2026)

[153]

Sáez-Llorens X, Beltran-Rodriguez J, Novoa Pizarro JM, Mensi I, Keshavan P, Toneatto D. Four-year antibody persistence and response to a booster dose of a pentavalent MenABCWY vaccine administered to healthy adolescents and young adults. Hum Vaccin Immunother 2018; 14(5): 1161-74.

[154]

Petousis-Harris H. Impact of meningococcal group B OMV vaccines, beyond their brief. Hum Vaccin Immunother 2018; 14(5): 1058-63.

[155]

Lu Y, Ma N, Cheng K, Liu G, Liang J, Xu C, et al. An OMV-based nanovaccine as antigen presentation signal enhancer for cancer immunotherapy. Adv Mater 2025: 2413392.

[156]

Balasubramanian K, Evangelopoulos M, Brown BS, Parodi A, Celia C, Iman KY, et al. Ghee butter as a therapeutic delivery system. J Nanosci Nanotechnol 2017; 17(2): 977-82.

[157]

Xuan L, Ju Z, Skonieczna M, Zhou PK, Huang R. Nanoparticles-induced potential toxicity on human health: applications, toxicity mechanisms, and evaluation models. MedComm 2023; 4(4): e327.

[158]

Dykman LA. Gold nanoparticles for preparation of antibodies and vaccines against infectious diseases. Expert Rev Vaccines 2020; 19(5): 465-77.

[159]

Emergex. Emergex announces positive phase I trial data for DengueTcPTM, its novel T cell-priming immune set-point candidate. Available at: https://www.gyldenpharma.com/emergex-announces-positive-phase-i-trial-data-for-denguetcp-its-novel-t-cell-priming-immune-set-point-candidate/. (Accessed January 30, 2026)

[160]

Kanekiyo M, Wei CJ, Yassine HM, McTamney PM, Boyington JC, Whittle JR, et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 2013; 499(7456): 102-6.

[161]

Yassine HM, Boyington JC, McTamney PM, Wei CJ, Kanekiyo M, Kong WP, et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat Med 2015; 21(9): 1065-70.

[162]

Nie J, Wang Q, Li C, Zhou Y, Yao X, Xu L, et al. Self-assembled multiepitope nanovaccine provides long-lasting cross-protection against influenza virus. Adv Healthc Mater 2024; 13(1): 2303531.

[163]

Wu X, Li W, Rong H, Pan J, Zhang X, Hu Q, et al. A nanoparticle vaccine displaying conserved epitopes of the preexisting neutralizing antibody confers broad protection against SARS-CoV-2 variants. ACS Nano 2024; 18(24): 17749-63.

[164]

Nelson SA, Richards KA, Glover MA, Chaves FA, Crank MC, Graham BS, et al. CD4 T cell epitope abundance in ferritin core potentiates responses to hemagglutinin nanoparticle vaccines. NPJ Vaccines 2022; 7(1): 124.

[165]

Zhao Y, Guo S, Liu J, Wang Y, Wang B, Peng C, et al. Adjuvant-free, self-assembling ferritin nanoparticle vaccine coupled with influenza virus hemagglutinin protein carrying M1 and PADRE epitopes elicits cross-protective immune responses. Front Immunol 2025; 16: 1519866.

[166]

Ahmadivand S, Krpetic Z, Martínez MM, Garcia-Ordoñez M, Roher N, Palić D. Self-assembling ferritin nanoplatform for the development of infectious hematopoietic necrosis virus vaccine. Front Immunol 2024; 15: 1346512.

[167]

Parodi A, Kostyushev D, Brezgin S, Kostyusheva A, Borodina T, Akasov R, et al. Biomimetic approaches for targeting tumor-promoting inflammation. Semin Cancer Biol 2022; 86(Pt 2): 555-67.

[168]

Brezgin S, Parodi A, Kostyusheva A, Ponomareva N, Lukashev A, Sokolova D, et al. Technological aspects of manufacturing and analytical control of biological nanoparticles. Biotechnol Adv 2023; 67: 108122.

[169]

Pan Y, Wu X, Liu L, Zhao C, Zhang J, Yang S, et al. Genetically engineered cytomembrane nanovaccines for cancer immunotherapy. Adv Healthc Mater 2024; 13(8): 2400068.

[170]

Zhao G, Wang Y, Xing S, Jiang Y, Ding J, Cai Y, et al. Exosome-based anticancer vaccines: from bench to bedside. Cancer Lett 2024; 595: 216989.

[171]

Kostyusheva A, Romano E, Yan N, Lopus M, Zamyatnin AA Jr, Parodi A. Breaking barriers in targeted therapy: advancing exosome isolation, engineering, and imaging. Adv Drug Deliv Rev 2025; 211: 115522.

[172]

Elliott RO, He M. Unlocking the power of exosomes for crossing biological barriers in drug delivery. Pharmaceutics 2021; 13(1): 122.

[173]

Brezgin S, Kostyusheva A, Ponomareva N, Bayurova E, Kondrashova A, Frolova A, et al. Hydroxychloroquine enhances cytotoxic properties of extracellular vesicles and extracellular vesicle-mimetic nanovesicles loaded with chemotherapeutics. Pharmaceutics 2023; 15(2): 534.

[174]

Zou Y, Li S, Li Y, Zhang D, Zheng M, Shi B. Glioblastoma cell derived exosomes as a potent vaccine platform targeting primary brain cancers and brain metastases. ACS Nano 2025; 19(18): 17309-22.

[175]

Ayyar KK, Moss AC. Exosomes in intestinal inflammation. Front Pharmacol 2021; 12: 1295.

[176]

Zhang H, Lin S, McElroy CL, Wang B, Jin D, Uteshev VV, et al. Circulating pro-inflammatory exosomes worsen stroke outcomes in aging. Circ Res 2021; 129(9): e121-40.

[177]

LeBleu VS, Kalluri R. Exosomes as a multicomponent biomarker platform in cancer. Trends Cancer 2020; 6(9): 767-74.

[178]

Brezgin S, Danilik O, Yudaeva A, Kachanov A, Kostyusheva A, Karandashov I, et al. Basic guide for approaching drug delivery with extracellular vesicles. Int J Mol Sci 2024; 25(19): 10401.

[179]

Harvey BT, Fu X, Li L, Neupane KR, Anand N, Kolesar JM, et al. Dendritic cell membrane-derived nanovesicles for targeted T cell activation. ACS Omega 2022; 7(50): 46222-33.

[180]

Viaud S, Ploix S, Lapierre V, Théry C, Commere PH, Tramalloni D, et al. Updated technology to produce highly immunogenic dendritic cell-derived exosomes of clinical grade: a critical role of interferon- γ . J Immunother 2011; 34(1): 65-75.

[181]

Munich S, Sobo-Vujanovic A, Buchser WJ, Beer-Stolz D, Vujanovic NL. Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands. Oncoimmunology 2012; 1(7): 1074-83.

[182]

Nikfarjam S, Rezaie J, Kashanchi F, Jafari R. Dexosomes as a cell-free vaccine for cancer immunotherapy. J Exp Clin Cancer Res 2020; 39(1): 258.

[183]

Escudier B, Dorval T, Chaput N, André F, Caby MP, Novault S, et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial. J Transl Med 2005; 3(1): 10.

[184]

Morse MA, Garst J, Osada T, Khan S, Hobeika A, Clay TM, et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med 2005; 3(1): 9.

[185]

Dai S, Wei D, Wu Z, Zhou X, Wei X, Huang H, et al. Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol Ther 2008; 16(4): 782-90.

[186]

Pitt JM, Charrier M, Viaud S, André F, Besse B, Chaput N, et al. Dendritic cell-derived exosomes as immunotherapies in the fight against cancer. J Immunol 2014; 193(3): 1006-11.

[187]

Alsaab HO, Alharbi FD, Alhibs AS, Alanazi NB, Alshehri BY, Saleh MA, et al. PLGA-based nanomedicine: history of advancement and development in clinical applications of multiple diseases. Pharmaceutics 2022; 14(12): 2728.

[188]

Chavan Y, Tambe S, Jain D, Khairnar S, Amin P. Redefining the importance of polylactide-co-glycolide acid (PLGA) in drug delivery. Ann Pharm Fr 2022; 80(5): 603-16.

[189]

Idumah CI. Emerging trends in poly (lactic-co-glycolic) acid bionanoarchitectures and applications. Cleaner Mater 2022; 5: 100102.

[190]

Sarkar C, Kommineni N, Butreddy A, Kumar R, Bunekar N, Gugulothu K. PLGA nanoparticles in drug delivery. In: Jana S, Jana S, editors. Nanoengineering of biomaterials. WILEY-VCH GmbH; 2022. p. 217-60.

[191]

Jan N, Madni A, Khan S, Shah H, Akram F, Khan A, et al. Biomimetic cell membrane-coated poly (lactic-co-glycolic acid) nanoparticles for biomedical applications. Bioeng Transl Med 2023; 8(2): e10441.

[192]

Alkilany AM, Rachid O, Alkawareek MY, Billa N, Daou A, Murphy CJ. PLGA-gold nanocomposite: preparation and biomedical applications. Pharmaceutics 2022; 14(4): 660.

[193]

Raj R, Pinto SN, Crucho CI, Das S, Baleizão C, Farinha JPS. Optically traceable PLGA-silica nanoparticles for cell-triggered doxorubicin delivery. Colloids Surf B Biointerfaces 2022; 220: 112872.

[194]

Ling X, Dong Z, He J, Chen D, He D, Guo R, et al. Advances in polymer-based self-adjuvanted nanovaccines. Small 2025; 21(5): 2409021.

[195]

El-Hammadi MM, Arias JL. Recent advances in the surface functionalization of PLGA-based nanomedicines. Nanomaterials (Basel) 2022; 12(7): 1046.

[196]

Sequeira JA, Pereira I, Ribeiro AJ, Veiga F, Santos AC. Surface functionalization of PLGA nanoparticles for drug delivery. Handbook of Functionalized Nanomaterials for Industrial Applications 2020: 185-203.

[197]

Hamdy S, Haddadi A, Hung RW, Lavasanifar A. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Adv Drug Deliv Rev 2011; 63(10-11): 943-55.

[198]

Amin MK, Boateng J. Surface functionalization of PLGA nanoparticles for potential oral vaccine delivery targeting intestinal immune cells. Colloids Surf B Biointerfaces 2023; 222: 113121.

[199]

Zhukova V, Osipova N, Semyonkin A, Malinovskaya J, Melnikov P, Valikhov M, et al. Fluorescently labeled plga nanoparticles for visualization in vitro and in vivo: the importance of dye properties . Pharmaceutics 2021; 13(8): 1145.

[200]

Chirizzi C, Gatti L, Sancho-Albero M, Sebastian V, Arruebo M, Uson L, et al. Optimization of superfluorinated PLGA nanoparticles for enhanced cell labelling and detection by 19F-MRI. Colloids Surf B Biointerfaces 2022; 220: 112932.

[201]

Operti MC, Bernhardt A, Grimm S, Engel A, Figdor CG, Tagit O. PLGA-based nanomedicines manufacturing: technologies overview and challenges in industrial scale-up. Int J Pharm 2021; 605: 120807.

[202]

Szachniewicz MM, Neustrup MA, van den Eeden SJ, van Meijgaarden KE, Franken KL, van Veen S, et al. Evaluation of PLGA, lipid-PLGA hybrid nanoparticles, and cationic pH-sensitive liposomes as tuberculosis vaccine delivery systems in a Mycobacterium tuberculosis challenge mouse model-A comparison. Int J Pharm 2024; 666: 124842.

[203]

Kim A, Xie F, Abed OA, Moon JJ. Vaccines for immune tolerance against autoimmune disease. Adv Drug Deliv Rev 2023; 203: 115140.

[204]

Koerner J, Horvath D, Herrmann VL, MacKerracher A, Gander B, Yagita H, et al. PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy. Nat Commun 2021; 12(1): 2935.

[205]

Creemers JH, Pawlitzky I, Grosios K, Gileadi U, Middleton MR, Gerritsen WR, et al. Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol. BMJ Open 2021; 11(8): e050725.

[206]

Freitas R, Ferreira E, Miranda A, Ferreira D, Relvas-Santos M, Castro F, et al. Targeted and self-adjuvated nanoglycovaccine candidate for cancer immunotherapy. ACS Nano 2024; 18(15): 10088-103.

[207]

Shi S, Zhu H, Xia X, Liang Z, Ma X, Sun B. Vaccine adjuvants: understanding the structure and mechanism of adjuvanticity. Vaccine 2019; 37(24): 3167-78.

[208]

Ruwona TB, Xu H, Li X, Taylor AN, Shi YC, Cui Z. Toward understanding the mechanism underlying the strong adjuvant activity of aluminum salt nanoparticles. Vaccine 2016; 34(27): 3059-67.

[209]

Ko EJ, Kang SM. Immunology and efficacy of MF59-adjuvanted vaccines. Hum Vaccin Immunother 2018; 14(12): 3041-5.

[210]

Calabro S, Tortoli M, Baudner BC, Pacitto A, Cortese M, O’Hagan DT, et al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 2011; 29(9): 1812-23.

[211]

Lodaya RN, Kanitkar AP, Friedrich K, Henson D, Yamagata R, Nuti S, et al. Formulation design, optimization and in vivo evaluations of an α-tocopherol-containing self-emulsified adjuvant system using inactivated influenza vaccine. J Control Release 2019; 316: 12-21.

[212]

Chen C, Zhang C, Li R, Wang Z, Yuan Y, Li H, et al. Monophosphoryl-lipid A (MPLA) is an efficacious adjuvant for inactivated rabies vaccines. Viruses 2019; 11(12): 1118.

[213]

Coccia M, Collignon C, Hervé C, Chalon A, Welsby I, Detienne S, et al. Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFN γ response promoting vaccine immunogenicity . NPJ Vaccines 2017; 2: 25.

[214]

Zhu D, Tuo W. QS-21: a potent vaccine adjuvant. Nat Prod Chem Res 2015; 3(4): e113.

[215]

Ou BS, Baillet J, Filsinger Interrante MV, Adamska JZ, Zhou X, Saouaf OM, et al. Saponin nanoparticle adjuvants incorporating Toll-like receptor agonists drive distinct immune signatures and potent vaccine responses. Sci Adv 2024; 10(27): eadn7187.

[216]

Saleemi MA, Zhang Y, Zhang G. Current progress in the science of novel adjuvant nano-vaccine-induced protective immune responses. Pathogens 2024; 13(6): 441.

[217]

Fehér K. Single stranded DNA immune modulators with unmethylated CpG motifs: structure and molecular recognition by toll-like receptor 9. Curr Protein Pept Sci 2019; 20(10): 1060-8.

[218]

Luo X, Song Z, Zeng X, Ye Y, Zheng H, Cai D, et al. A promising self-nanoemulsifying adjuvant with plant-derived saponin D boosts immune response and exerts an anti-tumor effect. Front Immunol 2023; 14: 1154836.

[219]

Chavda VP, Balar PC, Bezbaruah R, Vaghela DA, Rynjah D, Bhattacharjee B, et al. Nanoemulsions: summary of a decade of research and recent advances. Nanomedicine (Lond) 2024; 19(6): 519-36.

[220]

Li D, Li W, Li S, Zhang Y, Hu X, Liu S, et al. Fabrication of chitosan-based emulsion as an adjuvant to enhance nasal mucosal immune responses. Int J Biol Macromol 2024; 270(Pt 2): 132913.

[221]

Razim A, Pyclik M, Pacyga K, Górska S, Xu J, Olszewski MA, et al. Silicone oil-based nanoadjuvants as candidates for a new formulation of intranasal vaccines. Vaccines (Basel) 2021; 9(3): 234.

[222]

Ma Q, Mu Y, Gong L, Zhu C, Di S, Cheng M, et al. Manganese-based nanoadjuvants for enhancement of immune effect of DNA vaccines. Front Bioeng Biotechnol 2022; 10: 1053872.

[223]

Ross KA, Tingle AM, Senapati S, Holden KG, Wannemuehler MJ, Mallapragada SK, et al. Novel nanoadjuvants balance immune activation with modest inflammation: implications for older adult vaccines. Immun Ageing 2023; 20(1): 28.

[224]

Jin SM, Yoo YJ, Shin HS, Kim S, Lee SN, Lee CH, et al. A nanoadjuvant that dynamically coordinates innate immune stimuli activation enhances cancer immunotherapy and reduces immune cell exhaustion. Nat Nanotechnol 2023; 18(4): 390-402.

[225]

Sarah R. Is the Novavax COVID vaccine better than mRNA vaccines? What we know so far. Available at: https://www.scientificamerican.com/article/is-the-novavax-covid-vaccine-better-than-mrna-vaccines-what-we-know-so-far/. (Accessed January 30, 2026)

[226]

Novavax. Matrix-M® Adjuvant. Available at: https://www.novavax.com/science-technology/matrix-m-adjuvant. (Accessed January 30, 2026).

[227]

Morein B, Sundquist B, Höglund S, Dalsgaard K, Osterhaus A. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 1984; 308(5958): 457-60.

[228]

Drane D, Gittleson C, Boyle J, Maraskovsky E. ISCOMATRIXTM adjuvant for prophylactic and therapeutic vaccines . Expert Rev Vaccines 2007; 6(5): 761-72.

[229]

Manoff SB, Sausser M, Russell AF, Martin J, Radley D, Hyatt D, et al. Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a phase I randomized clinical trial in flavivirus-naïve adults. Hum Vaccin Immunother 2019; 15(7-8): 1580-8.

[230]

Puente-Massaguer E, Lecina M, Gòdia F. Application of advanced quantification techniques in nanoparticle-based vaccine development with the Sf9 cell baculovirus expression system. Vaccine 2020; 38(9): 1849-59.

[231]

Tian JH, Patel N, Haupt R, Zhou H, Weston S, Hammond H, et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat Commun 2021; 12(1): 372.

[232]

Parums DV. First approval of the protein-based adjuvanted nuvaxovid (NVX-CoV2373) novavax vaccine for SARS-CoV-2 could increase vaccine uptake and provide immune protection from viral variants. Med Sci Monit 2022; 28: e936523.

[233]

Deming ME, Lyke KE. A ‘mix and match’ approach to SARS-CoV-2 vaccination. Nat Med 2021; 27(9): 1510-11.

[234]

Smith G, Liu Y, Flyer D, Massare MJ, Zhou B, Patel N, et al. Novel hemagglutinin nanoparticle influenza vaccine with Matrix-MTM adjuvant induces hemagglutination inhibition, neutralizing, and protective responses in ferrets against homologous and drifted A (H3N2) subtypes . Vaccine 2017; 35(42): 5366-72.

[235]

Shinde V, Cho I, Plested JS, Agrawal S, Fiske J, Cai R, et al. Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial. Lancet Infect Dis 2022; 22(1): 73-84.

[236]

Qin L, Zhang H, Zhou Y, Umeshappa CS, Gao H. Nanovaccine-based strategies to overcome challenges in the whole vaccination cascade for tumor immunotherapy. Small 2021; 17(18): 2006000.

[237]

Fang X, Lan H, Jin K, Gong D, Qian J. Nanovaccines for cancer prevention and immunotherapy: an update review. Cancers (Basel) 2022; 14(16): 3842.

[238]

Gao X, Wang X, Li S, Saif Ur Rahman M, Xu S, Liu Y. Nanovaccines for advancing long-lasting immunity against infectious diseases. ACS Nano 2023; 17(24): 24514-24538.

[239]

Parodi A, Buzaeva P, Nigovora D, Baldin A, Kostyushev D, Chulanov V, et al. Nanomedicine for increasing the oral bioavailability of cancer treatments. J Nanobiotechnology 2021; 19(1): 354.

[240]

Gholap AD, Gupta J, Kamandar P, Bhowmik DD, Rojekar S, Faiyazuddin M, et al. Harnessing nanovaccines for effective immunization- a special concern on COVID-19: facts, fidelity, and future prospective. ACS Biomater Sci Eng 2023; 10(1): 271-97.

[241]

Zhang Y, Li M, Du G, Chen X, Sun X. Advanced oral vaccine delivery strategies for improving the immunity. Adv Drug Deliv Rev 2021; 177: 113928.

[242]

Zhang Y, Kang R, Zhang X, Pang G, Li L, Han C, et al. A programmable oral bacterial hydrogel for controllable production and release of nanovaccine for tumor immunotherapy. Biomaterials 2023; 299: 122147.

[243]

Gamallat Y, Meyiah A, Kuugbee ED, Hago AM, Chiwala G, Awadasseid A, et al. Lactobacillus rhamnosus induced epithelial cell apoptosis, ameliorates inflammation and prevents colon cancer development in an animal model. Biomed Pharmacother 2016; 83: 536-41.

[244]

Liotti F, Marotta M, Sorriento D, Pagliuca C, Caturano V, Mantova G, et al. Probiotic Lactobacillus rhamnosus GG (LGG) restrains the angiogenic potential of colorectal carcinoma cells by activating a proresolving program via formyl peptide receptor 1 . Mol Oncol 2022; 16(15): 2959-80.

[245]

Xu X, Zhang M, Liu X, Chai M, Diao L, Ma L, et al. Probiotics formulation and cancer nanovaccines show synergistic effect in immunotherapy and prevention of colon cancer. iScience 2023; 26(7): 107148.

[246]

Zu M, Ma Y, Zhang J, Sun J, Shahbazi MA, Pan G, et al. An oral nanomedicine elicits in situ vaccination effect against colorectal cancer . ACS Nano 2024; 18(5): 3651-3668.

[247]

Desai N, Chavda V, Singh TRR, Thorat ND, Vora LK. Cancer nanovaccines: nanomaterials and clinical perspectives. Small 2024; 20(15): 2401631.

[248]

Kaveh-Samani A, Dalali S, Kaviani F, Piri-Gharaghie T, Doosti A. Oral administration of DNA alginate nanovaccine induced immune-protection against Helicobacter pylori in Balb/C mice. BMC Immunol 2024; 25: 11.

PDF (2769KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉